bought my covered calls back today at a small profit. 853 info was not mature enough to generate any ASCO excitement, but I still have a feeling the company is on the upswing, gaining exposure, developing good new molecules, maybe some new partnerships when data matures. Now I just hope execs mess things up with an unexpected 2ndary, or negative 901 news. If they could just let the price rise...sign new development deals, don't try do phase III trials, just keep the pipeline moving and farm out advanced trials and commercialization IMO. Let the big boys do what they do best and focus on what IMGN does best, discovery and early development (John Lambert). That's the key to success IMO.
Tempted to cover to close my covered calls at strike price of 17.00 and then write a covered call for july at 18.00 to offset the costs. I hate buying back though. May just ride this out, and if I get called out next week I'll just buy back in and set a new strike price.